SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02924714

Recruitment Status : Recruiting

First Posted : October 5, 2016

Last Update Posted : April 10, 2018

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Øyvind Sverre Bruland, Oslo University Hospital

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	November 2022
Estimated Study Completion Date :	November 2022

Publications:

Hompland I, Bruland ØS. Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST? Anticancer Res. 2015 Nov;35(11):5759-65. Review.

To Top